Articles About Books And Publishing |
Stop Parking Domain Names Develop Your Domain Names |
|||||||
Ekomed Publishes Phase II Clinical Trial of Botanical Immunomodulator Dzherelo (Immunoxel)
Kiev, Ukraine (PRWEB) June 20, 2008 -- Ukrainian company Ekomed LLC announced this week that it had published Phase II clinical trial of its herbal supplement Dzherelo (Immunoxel) in patients with HIV and tuberculosis. The study appeared in June issue of International Immunopharmacology (2008; Volume 8(6): Pages 845-851). Abstract of the paper can be found online at PubMed -- medical information service of the National Institutes of Health (NIH): http://www.ncbi.nlm.nih.gov/pubmed/18442788?ordinalpos=1&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum
Open-label, Phase II clinical trial was conducted in 40 TB/HIV co-infected patients to evaluate the effect of oral immunomodulator Dzherelo (Immunoxel) on immune and viral parameters. The anti-retroviral therapy naïve patients were divided into two equal groups which received same anti-tuberculosis therapy (ATT). The arm A, which served as a control, received Isoniazid (H); Rifampicin (R); Pyrazinamide (Z); Streptomycin (S); and Ethambutol (E), and arm B received 50 drops of Dzherelo twice per day in addition to the daily dose of HRZSE. After 2 months the total CD3+ lymphocytes increased from 728 to 921 cells/¼l (P=0.025) in Dzherelo recipients, whereas in the control group they decreased from 651 to 585 cells (P=0.25). CD4 T-cell numbers expanded in Dzherelo arm (174 to 283; P=0.00003) but declined in ATT group (182 to 174; P=0.34). The ratio between CD4/CD8 cells improved in Dzherelo arm (1.244>1.536; P=0.007) but deteriorated in ATT arm (1.213>0.943; P=0.002). The percent of CD3+HLA-DR+ activated lymphocytes had fallen in ATT group (22.6>20.5; P=0.004), but rose in Dzherelo recipients (21.5>30.5; P=0.0001). The changes in CD20+ B lymphocytes were insignificant in both arms (28.4%>28.6%; P=0.4) and (27.2%>26.7%; P=0.38). No difference was seen in the amount of CD3-CD16+CD56+ natural killer (NK) cells in arm A (21.3%>22.6%; P=0.1), while in Dzherelo recipients they declined significantly (19.9%>14.5%; P=0.0026). The viral load, measured by plasma RNA-PCR, decreased in Dzherelo group (P=0.002), but increased in ATT group (P=0.03).
The study concluded that Dzherelo has a favorable effect on the immune status and viral burden in TB/HIV patients when given as the immunomodulating adjunct to TB drugs. Dzherelo is an extract from several plants grown in Ukraine that have been used safely as food or for medicinal purposes for several centuries. Being derived from botanical sources and with established record of safety since its approval by the Ministry of Health of Ukraine in 1997, Dzherelo has been used by an estimated 500,000 people so far.
Scientific Director of Ekomed, Mr. Volodymyr Pylypchuk, commented on this occasion: "The publication of our study in peer-reviewed journal is an important milestone for us. Our data shows that Dzherelo can be useful as an immune adjuvant for therapy of AIDS and tuberculosis -- two leading infectious diseases of global importance. Results of this Phase II trial support earlier clinical studies and confirm our commitment to the health of global community".
About Ekomed LLC Founded in 1996, Ekomed is a privately-held company based in Kiev, Ukraine. The company is the leading botanical company that manufactures over 26 different multiherbal preparations for a variety of health disorders. For more details, please visit the company website at www.ekomed.com.ua
Media contact: Volodymyr Pylypchuk CEO and Scientific Director Ekomed LLC 80-A Pravdy Avenue pylypchuk@bk.ru
# # #
This press release has been reprinted from PRWEB per the terms and conditions of the copyright notice.
Other Article Sites findabook.com moneycd.info a-mortgage.info
about-lemon-laws.info aboutstudentloans.info |
MORE ARTICLES: E-book Writing: Hidden Secrets Revealed for Successful E-book Writing 1. Develop short e-books. This is not exclusively to cut off your composing time in one-half but likewise to improve answer your latent customers. You find out, internet users are recognized to have a scant attention span and these folks choose purchasing short e-books as they do not get the time or the solitaire to pass hours studying writings barely to acquire the fact they require. Therefore to assist them out, you might option a real particular theme that you can talk about in 20-30 pages.
Buy Private Label E-book Resell Rights or Write Your Own E-book
How To Write And Publish Your Own Book
Write And Publish A Book Eureka Style!
How to Publish a Book: Key Differences Between Publishing and Self Publishing
Virtual Book Tour to Address Independent Book Publishing Questions at AskPhilDavis.com
Book Publishing - How I Got Into Book Publishing
Find, Review, Compare and Join a Canadian Book Club at Canada-Book-Clubs.com
Midwest Book Review Gives Thumbs-Up to Book Extolling Joys of Writing for Everyone
Zael Kho of Singapore Writes Fantasy Book Titled Sojourn, Published by Holy Fire Publishing
Writing Children's Books: Take Chances To Get Published
Two Books from Oceanview Publishing Among Winners of ForeWord Book of the Year Awards
Lincoln Institute Book 'Visualizing Density' Wins Award By Choice Magazine, Planetizen, New England Book Show
How To Get A Book Published - The Competition Is Tough In The Book Publishing Industry
How to Write and Publish a Book with Little or No Money
|
|||||||
| Develop Your Domain Names | Site Map | Home | ||||||||